All In Biotech

Drug Trial Radar · NCT05866627

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jul 4, 2023

Primary completion

Sep 29, 2023

Study completion Sep 29, 2023

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • FamotidineDrug

    Specified dose on specified days

  • AfimetoranDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 20 Days
  2. Time to attain maximum observed plasma concentration (Tmax)Time frame: Up to 20 Days
  3. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])Time frame: Up to 20 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Nottingham, Nottinghamshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.